WHO ICTRP trial
A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and…
JPRN-jRCT2031190264 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCT2031190264 |
|---|---|
| Public title | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults |
| Scientific title | A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults - Adaptive COVID-19 Treatment Trial (ACTT) |
| Primary sponsor | Ohmagari Norio |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | USA;Japan;KOREA;Japan |
| Conditions | Novel Coronavirus Infectious Disease (COVID-19) |
| Interventions | Dosing and Administration Subjects will be randomized 1:1 to receive either active product or placebo. Initially, the trial will have 2 arms: -Remdesivir will be administered as a 200 mg IV loading dose on Day 1, followed by a 100 mg… |
| Registration date | Mar 24, 2020 |
| Target size | 100 |
| Registry page | jrct.niph.go.jp |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: